Last reviewed · How we verify
Increased dose of Kaletra
Increased dose of Kaletra is a Small molecule drug developed by Community Research Initiative of New England. It is currently FDA-approved.
Increased dose of Kaletra, marketed by the Community Research Initiative of New England, is a well-established antiretroviral therapy. The key composition patent expires in 2028, providing a strong barrier to generic competition in the near term. The primary risk lies in the potential for new entrants or alternative therapies to erode market share as the patent expiration approaches.
At a glance
| Generic name | Increased dose of Kaletra |
|---|---|
| Sponsor | Community Research Initiative of New England |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- First in Human Study of TLC-ART 101 (ACTU 2001) (PHASE1)
- Trial of Treatments for COVID-19 in Hospitalized Adults (PHASE3)
- Covid-19 and Diabetes in West of Algeria
- Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV (PHASE2)
- Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy (PHASE4)
- Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
- The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet (PHASE1)
- BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Increased dose of Kaletra CI brief — competitive landscape report
- Increased dose of Kaletra updates RSS · CI watch RSS
- Community Research Initiative of New England portfolio CI